You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline characteristics and available endpoints about the trials of KEYNOTE-407 and IMpower 131

From: Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Items KEYNOTE-407 IMpower 131
Baseline Characteristics Pembro + CP/CnP (N = 278) Placebo + CP/CnP (N = 281) Atezo + CnP (N = 343) CnP (N = 340)
 Age, median (range), years 65.0 (29–87) 65.0 (36–88) 65 (23–83) 65 (38–86)
 Sex, male, n (%) 220 (79.1) 235 (83.6) 279 (81) 278 (82)
 Race, Asian, n (%) 54 (19.4) 52 (18.5) 41 (12) 37 (11)
 ECOG PS, 0, n (%) 73 (26.3) 90 (30.0) 115 (34) 110 (32)
 Former/current smoker, n (%) 256 (92.1) 262 (93.2) 311 (91) 216 (93)
PD-L1 expressiona, n (%)
 High 73 (26.3) 73 (26.0) 53 (15) 48 (14)
 Low 103 (37.1) 104 (37.0) 129 (38) 121 (36)
 Negative 95 (34.2) 99 (35.2) 160 (47) 171 (50)
Endpoints
 Median follow-up (months) 7.8 17.1
 OS (months), HR (95%CI, P) 15.9 vs. 11.3; 0.64 (0.49–0.85, P = 0.0008) 14.0 vs. 13.9 0.96 (0.78–1.18, P = 0.6931)
 PFS (months), HR (95%CI, P) 6.4 vs. 4.8 0.56 (0.45–0.70, P <0.0001) 6.3 vs. 5.6 0.71 (0.60–0.85, P = 0.0001)
 ORR (%) 59.4 vs. 38.0 49.3 vs. 41.2
 All cause AEs (%) 98.2 vs. 97.9 99.4 vs. 97.0
 Grade 3–5 AEs (%) 69.8 vs. 68.2 82.5 vs. 70.1
  1. Pembro Pembrolizumab, CP carboplatin and paclitaxel, CnP carboplatin and nab-paclitaxel, Atezo Atezolizumab, OS overall survival, PFS Progression-free survival, ORR objective response rate, AEs Adverse Events, HR hazard ratio, CI confidence interval
  2. aPD-L1 expression evaluation, KEYNOTE-407: The PD-L1 expression was assessed using the PD-L1 IHC 22C3 pharmDx assay, then determined by the Tumor Proportion Score (TPS) and classified into TPS < 1%, TPS 1 to 49% and TPS ≥50%. IMpower131: PD-L1 expression was evaluated using the VENTANA SP142 IHC assay. TC3 or IC3 (high) = TC ≥ 50% or IC ≥ 10% PD-L1+; TC1/2 or IC1/2 (low) = TC ≥ 1% and < 50% or IC ≥ 1% and < 10% PD-L1+; TC0 and IC0 (negative) = TC and IC < 1% PD-L1+. IC, tumor-infiltrating immune cell; TC, tumor cell